1-5 of 5
Christine R. Klaus
Close
Sort by
Journal Articles

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models

L. Danielle Johnston, Sarah Knutson, PhD, Natalie Warholic, Christine R Klaus, Tim J. Wigle, PhD, Dorothy Iwanowicz, Bruce A. Littlefield, PhD, Margaret Porter Scott, PhD, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Roy M. Pollock, PhD, Kevin W Kuntz, PhD, Heike Keilhack, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 4416.
https://doi.org/10.1182/blood.V122.21.4416.4416
Published: 2013
Journal Articles

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Christine R Klaus, Scott R. Daigle, PhD, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Edward J Olhava, PhD, Margaret Porter Scott, PhD, Roy M. Pollock, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 3930.
https://doi.org/10.1182/blood.V122.21.3930.3930
Published: 2013
Journal Articles

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Aravind Basavapathruni, Lei Jin, P. Ann Boriack-Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock
Journal: Blood
Blood (2013) 122 (6): 1017–1025.
https://doi.org/10.1182/blood-2013-04-497644
Published: 2013
Includes: Supplemental data
Journal Articles

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL -Rearranged Leukemia.

Roy M Pollock, PhD, Scott R Daigle, Carly A Therkelsen, Aravind Basavapathruni, PhD, Lei Jin, PhD, Christina J Allain, Christine R Klaus, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Edward J Olhava, PhD
Journal: Blood
Blood (2012) 120 (21): 2379.
https://doi.org/10.1182/blood.V120.21.2379.2379
Published: 2012
Journal Articles

Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice

Heike Keilhack, PhD, Akira Yokoi, PhD, Sarah K Knutson, PhD, Tim Wigle, PhD, Natalie Warholic, Satoshi Kawano, PhD, Yukinori Minoshima, PhD, Kuan-Chun Huang, PhD, Galina Kuznetsov, PhD, Namita Kumar, Christine R Klaus, Christina J Allain, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Toshimitsu Uenaka, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Roy M Pollock, PhD, Kevin W Kuntz, PhD
Journal: Blood
Blood (2012) 120 (21): 3712.
https://doi.org/10.1182/blood.V120.21.3712.3712
Published: 2012